The trial was assessing the efficacy of a fixed-dose combination of nivolumab and relatlimab in patients with microsatellite stable metastatic colorectal cancer whose disease has progressed after one to four prior lines of therapy.
Bristol Myers Squibb noted the trial’s cancellation was not due to safety concerns and said it will continue exploring the combination therapy as a potential treatment for other tumor types.
The drugmaker will also share data with investigators so they can determine next steps for patients currently enrolled in the trial.
Learn more here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
